Leramistat (HMC-C-01-A; MBS2320) is a mitochondrial complex 1 inhibitor, involving in cell metabolism immune metabolism regulation. Leramistat also inhibits ATP production in Thp1 human monocytes (IC50: 0.63 μM). Leramistat inhibits atopic dermatitis and other skin diseases autoimmune diseases, inflammatory diseases, cancer; and also inhibits osteoclast mediated disease.
Leramistat has moderate stability in rat hepatocytes, with a half-life of 7 min, and in human hepatocytes, a half-life of 154 min[2].
References:
[1]. Pokharel MD, et al. Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics. Redox Biol. 2024 Apr;70:103049.
[2]. Preparation of 1-metl-4-[(4-phenylphenyl)sulfonylmetl]cyclohexanol and 1-metl-4-[[4-(2-pyridyl)phenyl]sulfonylmetl]cyclohexanol compounds and their therapeutic use. World Intellectual Property Organization, WO2020035560 A1 2020-02-20. [3]. Preparation of N-(4-droxy-4-metl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-droxy-4-metl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use. World Intellectual Property Organization, WO2014207445 A1 2014-12-31.